N,N,4-trimethyl-3-oxopentanamide | 108350-14-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N,4-trimethyl-3-oxopentanamide
• CAS: 108350-14-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: YSPUSDPNKVHBIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N,4-trimethyl-3-oxopentanamide 在 四氯化钛 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 (1R^*, 2R^*)-N,N-dimethyl-2-hydroxy-2-isopropyl-4-methylenecyclopentanecarboxamide
  参考文献：
  名称：

  Chelation-controlled cyclization of β-ketoester-substituted and β-ketoamide-substituted allylsilanes.

  摘要：

  DOI：

  10.1016/s0040-4039(00)84729-2
• 作为产物：
  描述：

  6-isopropyl-2,2-dimethyl-2H,4H-1,3-dioxin-4-one 、 二甲胺 以 5,5-dimethyl-1,3-cyclohexadiene 、 乙醇 为溶剂， 反应 2.0h， 以345 mg的产率得到N,N,4-trimethyl-3-oxopentanamide
  参考文献：
  名称：

  Creation through Immobilization: A New Family of High Performance Heterogeneous Bifunctional Iminophosphorane (BIMP) Superbase Organocatalysts

  摘要：

  An immobilized chiral bifunctional iminophosphorane superbase organocatalyst has been developed and applied in a range of challenging enantioselective reactions. A unique feature of this novel catalytic system is that the final step creation of the iminophosphorane occurs at the point of immobilization. The utility of the immobilized catalyst system was demonstrated in the nitro-Mannich reaction of ketimines as well as the conjugate addition of high pK(a) 1,3-dicarbonyl pro-nucleophiles to nitrostyrene. Catalyst recycling was also demonstrated.

  DOI：

  10.1021/ol5029942

文献信息

• New Drug Delivery System for Crossing the Blood Brain Barrier
  申请人：Lipshutz H. Bruce

  公开号：US20070203080A1

  公开（公告）日：2007-08-30

  New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.

  新的泛醌类似物被披露，以及利用这些化合物将药物基团输送到人体的方法。
• Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias
  申请人：Bark Thomas

  公开号：US20130109662A1

  公开（公告）日：2013-05-02

  The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

  这项发明涉及铁（III）配合物和包括它们的药物组合物，用作药物，特别是用于治疗和/或预防缺铁症状和缺铁性贫血。
• FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES
  申请人：Zumes, LLC

  公开号：US20140039052A1

  公开（公告）日：2014-02-06

  This invention provides aqueous and non-aqueous clear formulations including at least one lipophilic bioactive molecules and an amphiphilic solubilizing agent. Exemplary aqueous formulations include a water-soluble reducing agent, which diminishes or prevents chemical degradation of the lipophilic bioactive molecule. The invention also provides methods of using the formulations of the invention. For example, the invention provides beverages including the formulations of the invention. The invention further provides methods of making the formulations and beverages.

  本发明提供了包括至少一种亲脂性生物活性分子和一种两性溶解剂的水性和非水性透明配方。其中，水性配方包括水溶性还原剂，可减少或防止亲脂性生物活性分子的化学降解。本发明还提供了使用该配方的方法。例如，本发明提供了包括该配方的饮料。本发明还提供了制备该配方和饮料的方法。
• PQS: A NEW HYDROTROPE FOR SOLUBILIZING LIPOPHILIC COMPOUNDS IN WATER
  申请人：Lipshutz H. Bruce

  公开号：US20070208088A1

  公开（公告）日：2007-09-06

  The present invention provides a solubilizing agent of the general formula: wherein R 11 , R 12 and R 13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. L1 and L2 are linker moieties, which are members independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl. Y1 and Y2 are hydrophilic moieties, which are members independently selected from polyethers, polyalcohols and derivatives thereof. Z1, Z2, Z3 and Z4 are members independently selected from 0 and 1, wherein at least one of Z1 and Z2 is 1.

  本发明提供了一种通式为的溶解剂剂：其中，R11、R12和R13分别是H、取代或未取代的烷基、取代或未取代的杂烷基、取代或未取代的环烷基、取代或未取代的杂环烷基、取代或未取代的芳基和取代或未取代的杂芳基中的独立成员。L1和L2是连接基，分别是取代或未取代的烷基和取代或未取代的杂烷基中的独立成员。Y1和Y2是亲水性基团，分别是聚醚、多元醇及其衍生物中的独立成员。Z1、Z2、Z3和Z4是独立选择的成员0和1，其中至少一个Z1和Z2为1。
• UBIQUINONE ANALOGS AND METHODS OF USE
  申请人：Lipshutz H. Bruce

  公开号：US20070208086A1

  公开（公告）日：2007-09-06

  New ubiquinone and ubiquinol analogs are disclosed, as well as methods of making and using these compounds.

  本发明揭示了新的泛醌和泛醌醇类似物，以及制备和使用这些化合物的方法。